Sarepta Therapeutics Faces Class Action Lawsuit Over Claims
Sarepta Therapeutics Faces Class Action Lawsuit Over Claims
Recently, a class action lawsuit was filed in the U.S. District Court concerning Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This lawsuit brings together investors who purchased or acquired securities during a specific period, signaling potential concerns about the company's practices and statements.
Details of the Lawsuit
Sarepta, known for its focus on genetic medicine, particularly the gene therapy product called ELEVIDYS, faces serious allegations. The claims highlight concerns about misinformation regarding the safety profile and clinical development of this product, which is aimed at treating Duchenne muscular dystrophy.
Allegations Raised
The allegations assert that Sarepta made false and misleading statements during the period of interest, impacting investors' decisions significantly. The specific accusations include:
- The company misrepresented the safety of ELEVIDYS, disregarding grave risks that were present.
- It failed to disclose severe adverse events that occurred during clinical trials.
- Essential information was withheld, leading to an eventual halt in dosing, regulatory scrutiny, and halted shipments.
- Positive statements about ELEVIDYS’s safety did not have a reasonable foundation.
Key Events Affecting Stock Performance
Several significant incidents have affected Sarepta's stock performance recently, indicating the turbulence investors are experiencing:
- Incident on March 18, 2025: Sarepta disclosed the tragic news of a patient who passed away while treated with ELEVIDYS. This disclosure led to a sharp drop in shares by 27.44%, bringing the closing price to $73.54.
- Incident on April 4, 2025: Following a call for a safety review from European regulators, Sarepta halted certain clinical studies. This action resulted in a fall of 7.13% in share value, ending the day at $54.43.
- Incident on June 15, 2025: Another alarming report indicated a second patient fatality due to acute liver failure. Consequently, shares plummeted by 42.12% to $20.91 as shipment suspensions were announced.
- Incident on June 24, 2025: The FDA issued a safety communication related to these patient deaths, causing shares to drop by an additional 8.01%, closing at $17.46 on June 25, 2025.
Investors' Next Steps
If you are someone who purchased Sarepta securities during the specified class period and suffered financial losses, it is important to note that there is a deadline approaching. By August 25, 2025, you have the opportunity to request to be appointed as a lead plaintiff in this matter.
Representation by Wolf Haldenstein
Wolf Haldenstein Adler Freeman & Herz LLP is representing those affected in this case. Established in 1888, this firm is dedicated to fighting for investors' rights who believe they have been misled. The firm's rich history in securities litigation means they bring over 125 years of expertise to the table.
Contact Information
For affected investors or those with information to share, it’s crucial to reach out. You can contact Wolf Haldenstein Adler Freeman & Herz LLP directly by calling (800) 575-0735 or (212) 545-4774. Additionally, Gregory Stone serves as the Director of Case and Financial Analysis if you need specific guidance.
Frequently Asked Questions
1. What is the lawsuit about?
The lawsuit centers around allegations that Sarepta Therapeutics misrepresented the safety of their gene therapy product, ELEVIDYS, affecting investor decisions.
2. Who can participate in the class action?
Investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, and who suffered financial losses are eligible to participate.
3. What should investors do now?
Affected investors should consider reaching out to legal representation to discuss their options before the August 25, 2025, deadline for appointing a lead plaintiff.
4. Who is Wolf Haldenstein?
Wolf Haldenstein is a law firm with over 125 years of experience in securities litigation, committed to protecting the rights of investors who have faced financial harm.
5. How can I contact Wolf Haldenstein?
You can contact the firm by phone at (800) 575-0735 or (212) 545-4774 to discuss your potential participation in the lawsuit.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
